Cargando…
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
BACKGROUND: Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived CD200 and its receptor on myeloid cells. We suggest that CD200/CD200R interactions on m...
Autores principales: | Moertel, Christopher L, Xia, Junzhe, LaRue, Rebecca, Waldron, Nate N, Andersen, Brian M, Prins, Robert M, Okada, Hideho, Donson, Andrew M, Foreman, Nicholas K, Hunt, Matthew A, Pennell, Christopher A, Olin, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296547/ https://www.ncbi.nlm.nih.gov/pubmed/25598973 http://dx.doi.org/10.1186/s40425-014-0046-9 |
Ejemplares similares
-
Use of CD200 blockade inhibitor to enhance glioma immunotherapy
por: Mesias, Elisabet, et al.
Publicado: (2015) -
Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma
por: Olin, Michael R., et al.
Publicado: (2019) -
Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
por: Choe, Deborah, et al.
Publicado: (2023) -
Understanding and overcoming the immunosuppressive effects of glioma induced immunosuppression
por: Moertel, Christopher, et al.
Publicado: (2013) -
CD200 promotes immunosuppression in the pancreatic tumor microenvironment
por: Choueiry, Fouad, et al.
Publicado: (2020)